Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study ; volume:14 ; number:2 ; year:2021 ; pages:706-715 ; extent:10
Case reports in oncology ; 14, Heft 2 (2021), 706-715 (gesamt 10)
- Urheber
- DOI
-
10.1159/000515416
- URN
-
urn:nbn:de:101:1-2021090900431306846394
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anžič, Nina
- Krasniqi, Fatime
- Eberhardt, Anna-Lena
- Tzankov, Alexandar
- Haslbauer, Jasmin Dionne
Ähnliche Objekte (12)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
Characterisation of fused in sarcoma deficient C57BL/6 mice
Pembrolizumab
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
Ipilimumab induced digital vasculitis
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Pembrolizumab for all
A 37-Year-Old Man with Myofibroblast Sarcoma Combined with Pleural Maculopathy: Case Report
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
Characterisation of fused in sarcoma deficient C57BL/6 mice
Pembrolizumab
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
Ipilimumab induced digital vasculitis
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Pembrolizumab for all
A 37-Year-Old Man with Myofibroblast Sarcoma Combined with Pleural Maculopathy: Case Report
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
Characterisation of fused in sarcoma deficient C57BL/6 mice
Pembrolizumab
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
Ipilimumab induced digital vasculitis
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Pembrolizumab for all